Genomics

Dataset Information

0

ArrayCGH profiles of endometrial cancer with and without prior prolonged tamoxifen treatment for primary breast cancer


ABSTRACT: Full title: comparison of the genomic (arrayCGH) profiles of endometrial cancer with and without prior prolonged tamoxifen treatment for primary breast cancer Purpose: Tamoxifen has been a very effective treatment for breast cancer for several decades, however, at the same time increases the risk of endometrial cancer, especially after prolonged exposure. In addition, tamoxifen has been associated with a higher proportion of unfavorable uterine tumor subtypes (carcinosarcomas and serous adenocarcinomas) with worse survival. We investigated whether endometrial tumors, which developed after prolonged tamoxifen treatment for breast cancer, are genetically different from endometrial tumors without preceding tamoxifen exposure. Experimental design: Array CGH was used on archival formalin-fixed paraffin embedded (FFPE) endometrial tumors to determine genomic aberrations. We compared the genomic profiles of 52 endometrial tumors from breast cancer patients after long-term (>=2 years) tamoxifen use (endometrioid adenocarcinomas n=26, carcinosarcomas n=14 and serous adenocarcinomas n=12) with endometrial tumors from unexposed breast cancer patients (n=45). Genomic profiles were correlated with tamoxifen exposure, tumor subtypes and histopathological characteristics of the endometrial tumors. Results: The common uterine corpus cancers of the endometrioid subtype show few genomic aberrations. Tumors with many genomic aberrations were in general ER-negative. In contrast, carcinosarcomas and serous adenocarcinomas showed many aberrations, however they were indistinguishable from each other. Tumors that developed after prolonged tamoxifen use did not show more or different aberrations than unexposed tumors. This was true for all tumor subtypes. Conclusion: Endometrial carcinomas that develop after prolonged tamoxifen use can not be distinguished from non-users on basis of their tumor genomic profile.

ORGANISM(S): Homo sapiens

PROVIDER: GSE16680 | GEO | 2010/06/17

SECONDARY ACCESSION(S): PRJNA117395

REPOSITORIES: GEO

Similar Datasets

2010-06-17 | E-GEOD-16680 | biostudies-arrayexpress
2017-03-07 | GSE94523 | GEO
2017-03-06 | GSE94031 | GEO
2020-05-05 | PXD017217 | Pride
2016-06-07 | GSE81213 | GEO
2012-11-01 | GSE33723 | GEO
| EGAS00001006453 | EGA
| EGAD00001009088 | EGA
| PRJNA117395 | ENA
2007-09-08 | E-GEOD-3013 | biostudies-arrayexpress